Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Common Equity (2020 - 2025)

BioAtla (BCAB) has disclosed Common Equity for 6 consecutive years, with -$36.2 million as the latest value for Q4 2025.

  • For Q4 2025, Common Equity fell 353.69% year-over-year to -$36.2 million; the TTM value through Dec 2025 reached -$36.2 million, down 353.69%, while the annual FY2025 figure was -$36.2 million, 353.69% down from the prior year.
  • Common Equity hit -$36.2 million in Q4 2025 for BioAtla, down from -$31.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $230.7 million in Q3 2021 and bottomed at -$36.2 million in Q4 2025.
  • Average Common Equity over 5 years is $98.7 million, with a median of $109.6 million recorded in 2023.
  • Year-over-year, Common Equity surged 440.04% in 2021 and then plummeted 353.69% in 2025.
  • BioAtla's Common Equity stood at $210.8 million in 2021, then fell by 14.46% to $180.3 million in 2022, then tumbled by 60.81% to $70.7 million in 2023, then crashed by 79.82% to $14.3 million in 2024, then tumbled by 353.69% to -$36.2 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$36.2 million, -$31.2 million, and -$16.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.